Scancell Holdings plc (SCLP) Ord GBP0.001
Sell:9.50pBuy:11.00p
0.25p
(2.50%)
- This stock can be held in a
Stocks and Shares ISA0.25p
(2.50%)0.25p
(2.50%)Company Information
About this company
Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.
Key people
Key facts
- EPICSCLP
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINGB00B63D3314
- Market cap£106.27m
- Employees61
- Shares in issue1.04bn
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.